Level C· Early human research exploring benefitsCase Report / SeriesPubMed

De novo CD5-positive diffuse large B cell lymphoma solely presenting as multiple subcutaneous nodules.

Takahashi T., Kazama Y., Shimizu H., Yoshimoto M., Tsujisaki M., Imai K.

Case Report / Series on Autoimmune Research, published in Acta Haematol (2002) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Acta Haematol (2002)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
12053152
DOI
10.1159/000058320

Abstract (original English)

Lymphomas may involve the subcutaneous tissue as a manifestation of generalized disease. However, they rarely present with multiple involvement of the subcutaneous fat tissue without other sites of the disease. We describe a patient with CD5+ diffuse large B cell lymphoma (DLBL) that was confined to the subcutaneous tissue. A 74-year-old woman with rheumatoid arthritis was admitted because of multiple subcutaneous nodules. The patient had not been treated with cytotoxic drugs or methotrexate. The biopsied specimen disclosed diffuse infiltration of large cells with a starry sky-like appearance. The cells were positive for CD5, CD19, CD20, CD25, IgM, lambda-chain, and negative for CD10, CD23 or cyclin D1. Thus a diagnosis of CD5+ DLBL was made. The patient was treated with a modified CHOP protocol and complete remission was achieved.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAgedAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsArthritis, RheumatoidB-LymphocytesBiomarkers, TumorBiopsyCD5 AntigensConnective Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research